Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02203825

Recruitment Status : Completed

First Posted : July 30, 2014

Last Update Posted : June 1, 2018

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Dana-Farber Cancer Institute

National Heart, Lung, and Blood Institute (NHLBI)

Information provided by (Responsible Party):

Celyad Oncology SA

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	March 2018
Actual Study Completion Date :	March 2018

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Murad JM, Baumeister SH, Werner L, Daley H, Trebeden-Negre H, Reder J, Sentman CL, Gilham D, Lehmann F, Snykers S, Sentman ML, Wade T, Schmucker A, Fanger MW, Dranoff G, Ritz J, Nikiforow S. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. Cytotherapy. 2018 Jul;20(7):952-963. doi: 10.1016/j.jcyt.2018.05.001. Epub 2018 Jun 29.

To Top